Brivaracetam augments short‐term depression and slows vesicle recycling
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Brivaracetam (BRV) decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle glycoprotein 2A (SV 2A) with a higher affinity than the antiepileptic drug levetiracetam (LEV). Experiments were performed to determine if BRV acted similarly to LEV to induce or augment short‐term depression (STD) under high‐frequency neuronal stimulation and slow synaptic vesicle recycling. Methods: Electrophysiologic field excitatory postsynaptic potential (f EPSP) recordings were made from CA 1 synapses in rat hippocampal slices loaded with BRV or LEV during intrinsic activity or with BRV actively loaded during hypertonic stimulation. STD was examined in response to 5 or 40 Hz stimulus trains. Presynaptic release of FM 1‐43 was visualized using two‐photon microscopy to assess drug effects upon synaptic vesicle mobilization. Results: When hippocampal slices were incubated in 0.1–30 μ m BRV or 30 μ m–1 m m LEV for 3 h, the relative CA 1 field EPSP s decreased over the course of a high‐frequency train of stimuli more than for control slices. This STD was frequency‐ and concentration‐dependent, with BRV being 100‐fold more potent than LEV. The extent of STD depended on the length of the incubation time for both drugs. Pretreatment with LEV occluded the effects of BRV. Repeated hypertonic sucrose treatments and train stimulation successfully unloaded BRV from recycling vesicles and reversed BRV s effects on STD, as previously reported for LEV. At their maximal concentrations, BRV slowed FM 1‐43 release to a greater extent than in slices loaded with LEV during prolonged stimulation. Significance: BRV, similar to LEV, entered into recycling synaptic vesicles and produced a frequency‐dependent decrement of synaptic transmission at 100‐fold lower concentrations than LEV. In addition, BRV slowed synaptic vesicle mobilization more effectively than LEV, suggesting that these drugs may modify multiple functions of the synaptic vesicle protein SV 2A to curb synaptic transmission and limit epileptic activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rizzoli, S. O., & Betz, W. J. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1583 · Cited by 975
Short-term forms of presynaptic plasticity
Fioravante, D., & Regehr, W. G. (2011) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.02.003 · Cited by 375 · cited 1×
“Although 5-Hz stimulation significantly diminished later pulses in the presence of LEV or BRV, this was not studied further because STD is less apparent at low frequencies.(13)”
BackgroundSynaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Cotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164 · cited 1×
“It seems plausible that LEV and BRV somehow alter SV2A’s interaction with one of its putative binding partners, which include synaptotagmin, multiple adapter proteins, Ca/calmodulindependent protein kinase II , an endophilin-like protein, and an epidermal growth factor receptor.(8,9) Because these proteins all partici…”
BackgroundWyllie, D. J. A., Manabe, T., & Nicoll, R. A. (1994) · Neuron · doi:10.1016/0896-6273(94)90158-9 · Cited by 112
Zhang, N., Gordon, S. L., Fritsch, M. J., Esoof, N., Campbell, D. G., Gourlay, R., Velupillai, S., Macartney, T., Peggie, M., van Aalten, D. M. F., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4248-14.2015 · Cited by 72 · cited 1×
“Because SV2A binds to and traffics synaptotagmin into vesicles,(8,34,35) a possible role for their association may be to position synaptotagmin optimally for initiating endocytosis or to clear synaptotagmin from the vicinity of the unzippering SNARE complex.(34,35) If BRV or LEV binding interfered with SV2A traffickin…”
Background
Research works printed but not linked: 34
- 10.1111/epi.12433 · DOI · Paper page
- Kaminski RM, 2012, Targeting SV2A for Discovery of Antiepileptic Drugs. Jasper's Basic Mechanisms of the Epilepsies [Internet]
- 10.1016/j.ejphar.2011.04.064 · DOI · Paper page
- 10.1124/mol.111.076687 · DOI
- 10.1111/cns.12347 · DOI · Paper page
- 10.1016/S0896-6273(00)81046-6 · DOI · Paper page
- 10.1074/jbc.M800738200 · DOI · Paper page
- 10.1016/j.seizure.2009.07.004 · DOI
- 10.1111/j.1528-1167.2006.01132.x · DOI · Paper page
- 10.1152/jn.00279.2011 · DOI · Paper page
- 10.1146/annurev.physiol.64.092501.114547 · DOI · Paper page
- 10.1038/2822 · DOI · Paper page
- 10.1038/bjp.2008.198 · DOI · Paper page
- 10.1074/jbc.C114.584516 · DOI · Paper page
- 10.1042/BST0391341 · DOI · Paper page
- 10.1038/nmeth.2019 · DOI · Paper page
- 10.1109/83.650848 · DOI · Paper page
- 10.1016/j.eplepsyres.2015.08.006 · DOI
- 10.1113/jphysiol.1967.sp008183 · DOI · Paper page
- 10.1002/jcp.20551 · DOI · Paper page
- 10.1016/S0896-6273(04)00113-8 · DOI · Paper page
- 10.1038/nn.2838 · DOI · Paper page
- 10.1126/science.1553547 · DOI · Paper page
- 10.1016/S0896-6273(00)00098-2 · DOI · Paper page
- 10.1523/JNEUROSCI.4500-05.2006 · DOI
- 10.1016/j.neuron.2013.08.010 · DOI
- 10.3389/fnsyn.2010.00144 · DOI · Paper page
- 10.1074/jbc.271.44.27770 · DOI · Paper page
- 10.1523/JNEUROSCI.4051-06.2007 · DOI · Paper page
- 10.1523/JNEUROSCI.0924-08.2008 · DOI · Paper page
- 10.1074/jbc.M113.512814 · DOI
- 10.1111/epi.12930 · DOI · Paper page
- 10.1016/0076-6879(91)02027-7 · DOI
- 10.1038/nprot.2011.414 · DOI
Cited by
Hassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
Klitgaard, H., Matagne, A., Nicolas, J., Gillard, M., Lamberty, Y., De Ryck, M., Kaminski, R. M., Leclercq, K., Niespodziany, I., Wolff, C., et al. (2016) · Epilepsia · doi:10.1111/epi.13340 · Cited by 168
Self-citationThe Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
A review of the pharmacology and clinical efficacy of brivaracetam
Klein, P., Diaz, A., Gasalla, T., & Whitesides, J. (2018) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s114072 · Cited by 99
“Rat hippocampal slice research comparing BRV and LEV using high-frequency neuronal stimulation have suggested that BRV augments synaptic depression and decreases synaptic transmission at 100-fold lower concentrations than LEV.(40) In studies with dye-loaded vesicles, BRV slowed stimulation-induced vesicle release sign…”
BackgroundInfluential
Metadata
- Authors
- Yang, X., Bognar, J., He, T., Mohammed, M., Niespodziany, I., Wolff, C., Esguerra, M., Rothman, S. M., & Dubinsky, J. M.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2015-10-30
- Volume
- 56
- Issue
- 12
- Pages
- 1899-1909
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1943229448
- Cited by
- 47
- References
- 6
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- UCB Pharma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.